Ergül Eyol
- Co-authors
- Martin R. BergerHassan AdwanMichael ZeppJörg KleeffAnnemarie BoleijAndrew L. LewisMartin FrankFrank Bergmann
- Topics
- Toxin Mechanisms and Immunotoxins (4 papers)Bioactive Compounds and Antitumor Agents (3 papers)Bone and Dental Protein Studies (3 papers)
- Partner nations
- GermanyTürkiyeUnited States
In The Last Decade
Ergül Eyol
17 papers receiving 298 citations
Peers
Comparison fields: 5 of 64
- Molecular Biology 143
- Oncology 83
- Immunology 72
- Cancer Research 52
- Plant Science 41
Countries citing papers authored by Ergül Eyol
This map shows the geographic impact of Ergül Eyol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ergül Eyol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ergül Eyol more than expected).
Fields of papers citing papers by Ergül Eyol
This network shows the impact of papers produced by Ergül Eyol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ergül Eyol. The network helps show where Ergül Eyol may publish in the future.
Co-authorship network of co-authors of Ergül Eyol
This figure shows the co-authorship network connecting the top 25 collaborators of Ergül Eyol. A scholar is included among the top collaborators of Ergül Eyol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ergül Eyol. Ergül Eyol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 4 | |
| 2 | 30 | |
| 3 | 1 | |
| 4 | 13 | |
| 5 | 2 | |
| 6 | 1 | |
| 7 | 6 | |
| 8 | 6 | |
| 9 | 15 | |
| 10 | 30 | |
| 11 | 25 | |
| 12 | 4 | |
| 13 | 34 | |
| 14 | 35 | |
| 15 | Identification and characterization of riproximin, a new type II ribosome-inactivating protein with potent anticancer activity, from aqueous Ximenia americana extracts used by African traditional medicine | 4 |
| 16 | 42 | |
| 17 | 52 |
About Ergül Eyol
Ergül Eyol is a scholar working on Toxicology, Biotechnology and Complementary and Manual Therapy, having authored 17 papers that have together received 304 indexed citations. Recurring topics across this work include Toxin Mechanisms and Immunotoxins (4 papers), Bioactive Compounds and Antitumor Agents (3 papers) and Bone and Dental Protein Studies (3 papers). The work is most often cited by research in Biotechnology (36 citations), Cancer Research (52 citations) and Immunology (72 citations). Ergül Eyol has collaborated with scholars based in Germany, Türkiye and United States. Frequent co-authors include Martin R. Berger, Hassan Adwan, Michael Zepp, Jörg Kleeff, Annemarie Boleij, Andrew L. Lewis, Martin Frank, Frank Bergmann, Claus‐W. von der Lieth and Rachel R. Taylor. Their work appears in journals such as Cancer Research, The FASEB Journal and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.